Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD30.CAR-T for Relapsed/Refractory Classical Hodgkin Lymphoma
NCT04268706Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Feb 2021
- Primary completion
- May 2025
- Countries
- 1
- Sponsor
- Tessa Therapeutics
- Modality
- CAR-T Cells
- Conditions
- classical Hodgkin lymphoma (cHL)
01
Overview
Phase 2, open-label, single-arm trial of autologous CD30.CAR-T in classical Hodgkin lymphoma (cHL), sponsored by Tessa Therapeutics. Primary endpoints: Safety of autologous CD30.CAR-T at 24 months and Objective Response Rate at 6 weeks. Started Feb 2021; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
CD30 positive r/r classical Hodgkin Lymphoma
Patients receive lymphodepletion followed by autologous CD30.CAR-T cells.
03
Who it enrols
Patients aged 12-75 with relapsed/refractory CD30+ classical Hodgkin Lymphoma who have failed at least 3 prior lines of therapy (including chemotherapy, brentuximab vedotin, and a PD-1 inhibitor).
04
Endpoints
Primary
Safety of autologous CD30.CAR-T
Objective Response Rate
Secondary
Objective Response Rate
Duration of Response
Progression Free Survival
Overall Survival
Health Related Quality of Life
Adverse Events
Beyond the preview
Go deeper on NCT04268706.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268706.